Ovatodiolide is a broad anticancer agent. It acts by upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway. References: Tu YX, Wang SB, Fu LQ, Li SS, Guo QP, Wu Y, Mou XZ, Tong XM. Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway. Oncotarget. 2017 Dec 14;9(3):3267-3277. doi: 10.18632/oncotarget.23231. eCollection 2018 Jan 9. PubMed PMID: 29423045; PubMed Central PMCID: PMC5790462.

纯度：≥98%

CAS：3484-37-5